MMP9 mediates MICA shedding in human osteosarcomas

Cell Biology International

Volumn 35, Issue 6, 2011, Pages 569-574

  Sun, Dahui ^a   Wang, Xu ^a   Zhang, Haixia ^b   Deng, Lijuan ^b   Zhang, Yan ^a,b  

^a JILIN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Immunoescape; MICA; MMP9; NKG2D; Osteosarcoma; Proteolytic cleavage

Indexed keywords

GELATINASE B; HLA A ANTIGEN;

ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; OSTEOSARCOMA; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; ZYMOGRAPHY;

CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MATRIX METALLOPROTEINASE 9; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OSTEOSARCOMA; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY;

EID: 79955745583     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20100431     Document Type: Article

References (29)

1. Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, Versari M, Picci P. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005;44:748-55.
2. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994;91:6259-63.
3. Begum S, Zhang Y, Shintani T, Toratani S, Sato JD, Okamoto T. Immunohistochemical expression of heparin-binding protein 17/ fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis. Oncol Rep 2007;17:591-6.
4. Busche A, Goldmann T, Naumann U, Steinle A, Brandau S. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther 2006;17:135-46.
5. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001;98:11521-6.
6. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005;104:2214-21.
7. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
10. Fan DG, Dai JY, Tang J, Wu MM, Sun SG, Jiang JL, Fan QY. Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. Cell Biol Int 2009;33:1263-7.
11. Galewska Z, Romanowicz L, Jaworski S, Bań kowski E. Matrix metalloproteinases, MMP-7 and MMP-26, in plasma and serum of control and preeclamptic umbilical cord blood. Eur J Obstet Gynecol Reprod Biol 2010;150:152-6.
12. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
13. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006;118:684-7.
14. Jackson BC, Nebert DW, Vasiliou V. Update of human and mouse matrix metalloproteinase families. Hum Genomics 2010;4:194-201.
15. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003;104:354-61.
16. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V, Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007;447:482-6.
17. Kim SY, Helman LJ. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 2010;152:517-28.
18. Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity 1999;10:577-84.
19. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
20. Lu SM, Xiao P, Xue L, Che LH, Yang P, Li Y, Qiao H. Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma. Neoplasma 2008;55:266-72.
21. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, Ellis I, Durrant LG. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 2007;7:17.
22. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-37.
23. Segarra M, Garci{dotless}́a-Marti{dotless}́nez A, Sá nchez M, Herná ndez-Rodri{dotless}́guez J, Lozano E, Grau JM, Cid MC. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007;66:1429-35.
24. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202:583-8.
25. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumorassociated MICA is shed by ADAM proteases. Cancer Res 2008;68:6368-76.
26. Xin ZF, Kim YK, Jung ST. Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 2009;28:105.
27. Yamamoto K, Fujiyama Y, Andoh A, Bamba T, Okabe H. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta 2001;1526:10-2.
28. Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL, Okamoto T. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci USA 2001;98:11336-40.
29. Zhuge Y, Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell invasion across collagen barrier. J Biol Chem 2001;276:16248-56.